English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Maternal serum screening for birth defects began in the early 1970s with the discovery of serum alpha-fetoprotein in the second trimester. It was found to be increased in fetuses with only open neural tube defects [1]. The book explains the advent of the serum screening for open neural tube defects. Indeed, the use of multiples of median (MoMs) to report results was partly adopted because of vast interlaboratory differences [1]. However, now in today’s era of excellent USG machines and experts in the field of imaging, we have now shifted our focus from

Sharad Gogate: Guidelines and Standards for Maternal Serum Screening for Down’s Syndrome, Neural Tube Defects, and Other Obstetric Problems